Skip to main content

Table 1 Response rates in phase 3 studies comparing imatinib with nilotinib or dasatinib

From: Advances in the treatment of chronic myeloid leukemia

  DASISION ENESTnd
Median follow-up (months) 18 NR
Minimum follow-up (months) 16 24
  Dasatinib 100 mg QD Imatinib 400 mg QD Nilotinib 300 mg BID Nilotinib 400 mg BID Imatinib 400 mg QD
  (N = 259) (N = 260) (N = 282) (N = 281) (N = 283)
Confirmed complete cytogenetic response by 18 mo (%) 78 70 NR NR NR
Major molecular response at any time (%) 57 41 71 67 44
Complete molecular response at any time (%) 13 7 26 21 10
Overall survival (%) 96.0 97.9 97.4 97.8 96.4
Progression-free survival (%) 94.9 93.7 98 97.7 95.2
Discontinued treatment (%) 19 20 26 22 33
  1. Data are based on the update reported at the 2010 Annual Meeting of the American Society of Hematology in Orlando, FL. NR = not reported